Essential Partners’s Protara Therapeutics TARA Stock Holding History

Essential Partners’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$33.1K	Buy	10,842 +1,040	+11%	+$4.05K	0.02%	755
2026 Q2	$37.4K	Sell	9,802 -70	-0.7%	-$333	0.02%	689
2026 Q1	$51.4K	Buy	9,872 +77	+0.8%	+$456	0.02%	594
2025 Q4	$52.2K	Buy	9,795 +3,847	+65%	+$21.4K	0.02%	597
2025 Q3	$25.9K	Buy	+5,948	New	+$19.3K	0.01%	807

Other funds holding TARA

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners's TARA Position: Q3 2026 in Review

Essential Partners increased its Protara Therapeutics (TARA) stake by 11% in Q3 2026, buying an estimated $4.05K and bringing the position to 10,842 shares worth $33.1K. The position accounts for 0.02% of the portfolio, ranked #755.

Essential Partners first reported a position in TARA in Q3 2025 and has held it in 5 quarters since. The position peaked at $52.2K in Q4 2025. 3 funds tracked by Wall St. Rank hold TARA as of Q3 2026.

Essential Partners held 10,842 shares of Protara Therapeutics worth $33.1K as of Q3 2026.
Essential Partners bought 1,040 Protara Therapeutics shares in Q3 2026, an estimated $4.05K.
Protara Therapeutics made up 0.02% of Essential Partners's portfolio in Q3 2026, its #755 holding.
Essential Partners first reported a position in Protara Therapeutics in Q3 2025 and has held it in 5 quarters since.
Essential Partners's Protara Therapeutics position peaked at $52.2K in Q4 2025.
3 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.